Rhumbline Advisers increased its holdings in shares of Cooper Companies, Inc. (The) (NYSE:COO) by 1.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,796 shares of the medical device company’s stock after buying an additional 1,300 shares during the quarter. Rhumbline Advisers owned 0.20% of Cooper Companies, Inc. (The) worth $23,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Advisor Group Inc. grew its stake in Cooper Companies, Inc. (The) by 5.3% during the 3rd quarter. Advisor Group Inc. now owns 5,951 shares of the medical device company’s stock worth $1,412,000 after buying an additional 298 shares during the last quarter. Toronto Dominion Bank grew its stake in Cooper Companies, Inc. (The) by 12.0% during the 3rd quarter. Toronto Dominion Bank now owns 18,536 shares of the medical device company’s stock worth $4,395,000 after buying an additional 1,984 shares during the last quarter. New York State Common Retirement Fund grew its stake in Cooper Companies, Inc. (The) by 0.5% during the 3rd quarter. New York State Common Retirement Fund now owns 226,107 shares of the medical device company’s stock worth $53,612,000 after buying an additional 1,200 shares during the last quarter. CIBC Asset Management Inc grew its stake in Cooper Companies, Inc. (The) by 8.6% during the 3rd quarter. CIBC Asset Management Inc now owns 5,101 shares of the medical device company’s stock worth $1,209,000 after buying an additional 404 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new position in Cooper Companies, Inc. (The) during the 3rd quarter worth $223,000. Hedge funds and other institutional investors own 95.23% of the company’s stock.

Several analysts have weighed in on the company. Zacks Investment Research downgraded Cooper Companies, Inc. (The) from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Robert W. Baird reiterated a “buy” rating and set a $267.00 price target (up previously from $251.00) on shares of Cooper Companies, Inc. (The) in a research note on Sunday, September 3rd. KeyCorp reiterated a “hold” rating on shares of Cooper Companies, Inc. (The) in a research note on Monday, August 28th. Piper Jaffray Companies boosted their price target on Cooper Companies, Inc. (The) from $265.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, September 1st. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $250.00 price target on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, September 12th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $260.22.

Cooper Companies, Inc. (COO) opened at $238.65 on Monday. The stock has a market capitalization of $11,680.00, a PE ratio of 25.52, a PEG ratio of 2.05 and a beta of 0.55. The company has a quick ratio of 1.29, a current ratio of 2.51 and a debt-to-equity ratio of 0.38. Cooper Companies, Inc. has a fifty-two week low of $158.73 and a fifty-two week high of $256.39.

Cooper Companies, Inc. (The) (NYSE:COO) last issued its quarterly earnings data on Thursday, August 31st. The medical device company reported $2.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.06. The business had revenue of $556.00 million during the quarter, compared to analysts’ expectations of $552.32 million. Cooper Companies, Inc. (The) had a return on equity of 16.00% and a net margin of 16.45%. The company’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.30 EPS. sell-side analysts expect that Cooper Companies, Inc. will post 9.72 earnings per share for the current year.

In related news, Director Gary S. Petersmeyer sold 3,977 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $244.94, for a total value of $974,126.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/11/20/cooper-companies-inc-the-coo-shares-bought-by-rhumbline-advisers.html.

Cooper Companies, Inc. (The) Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies, Inc. (The) (NYSE:COO).

Institutional Ownership by Quarter for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.